New basal cell carcinoma susceptibility loci

Nature Communications

Volumn 6, Issue , 2015, Pages

  Stacey, Simon N ^a   Helgason, Hannes ^a   Gudjonsson, Sigurjon A ^a   Thorleifsson, Gudmar ^a   Zink, Florian ^a   Sigurdsson, Asgeir ^a   Kehr, Birte ^a   Gudmundsson, Julius ^a   Sulem, Patrick ^a   Sigurgeirsson, Bardur ^b,c   Benediktsdottir, Kristrun R ^b,c   Thorisdottir, Kristin ^b,c   Ragnarsson, Rafn ^b,c   Fuentelsaz, Victoria ^d   Corredera, Cristina ^e   Gilaberte, Yolanda ^f   Grasa, Matilde ^g   Planelles, Dolores ^h   Sanmartin, Onofre ^i,j   Rudnai, Peter ^k   Gurzau, Eugene ^l   Koppova, Kvetoslava ^m   Nexø, Bjørn A ⁿ   Tjønneland, Anne ^o   Overvad, Kim ⁿ   Jonasson, Jon G ^b,c,p   Tryggvadottir, Laufey ^c,p   Johannsdottir, Hrefna ^a   Kristinsdottir, Anna M ^a   Stefansson, Hreinn ^a   Masson, Gisli ^a   Magnusson, Olafur T ^a   Halldorsson, Bjarni V ^a,q   Kong, Augustine ^a   Rafnar, Thorunn ^a   Thorsteinsdottir, Unnur ^a,c   Vogel, Ulla ^r   Kumar, Rajiv ^s   Nagore, Eduardo ^i,j   Mayordomo, José I ^t   Gudbjartsson, Daniel F ^a   Olafsson, Jon H ^b,c   Stefansson, Kari ^a,c   more..

^a DECODE GENETICS   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c UNIVERSITY OF ICELAND   (Iceland)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e Division of Dermatology Quiron Hospital   (Spain)

^f San Jorge General Hospital   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h Laboratorio de Inmunología Leucoplaquetar   (Spain)

ⁱ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^j UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^k NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH   (Hungary)

^l BABE BOLYAI UNIVERSITY   (Romania)

^m Regional Authority of Public Health   (Slovakia)

ⁿ AARHUS UNIVERSITY   (Denmark)

^o DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^p ICELANDIC CANCER REGISTRY   (Iceland)

^q REYKJAVIK UNIVERSITY   (Iceland)

^r NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^s GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^t UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 3; ALS2CR12 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; CASPASE 8; GATA3 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MYCN PROTEIN, HUMAN; N MYC PROTO ONCOGENE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN; TRANSCRIPTION FACTOR; ZFHX4 PROTEIN, HUMAN;

CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENETIC MARKER; GENOMICS; NEW RECORD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BINDING SITE; CANCER RISK; CANCER SUSCEPTIBILITY; CASP8 ALS2CR12 GENE; CHROMOSOME 10P; CHROMOSOME 2Q; CHROMOSOME 8Q; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE; HETEROZYGOTE; HUMAN; ICELANDER; INDEL MUTATION; INTRON; MAJOR CLINICAL STUDY; MALE; MYCN GENE; NONSENSE MEDIATED MRNA DECAY; PROTEIN DOMAIN; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ZFHX4 GENE; ADOLESCENT; CASE CONTROL STUDY; CAUCASIAN; CHILD; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; ICELAND; MIDDLE AGED; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; CASE-CONTROL STUDIES; CASPASE 8; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HOMEODOMAIN PROTEINS; HUMANS; ICELAND; MALE; MIDDLE AGED; N-MYC PROTO-ONCOGENE PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTEINS; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84927605530     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7825     Document Type: Article

References (68)

1. Epstein, E. H. Basal cell carcinomas: attack of the hedgehog. Nat. Rev. Cancer 8, 743-754 (2008).
2. Mohan, S. V. & Chang, A. L. S. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr. Dermatol. Rep. 3, 40-45 (2014).
3. Scherer, D. & Kumar, R. Genetics of pigmentation in skin cancer - a review. Mutat. Res. 705, 141-153 (2010).
4. Fan, Z. et al. A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. J. Med. Genet. 45, 303-308 (2008).
5. Pastorino, L. et al. Identification of a SUFU germline mutation in a family with Gorlin syndrome. Am. J. Med. Genet. A 149A, 1539-1543 (2009).
6. Smyth, I. et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum. Mol. Genet. 8, 291-297 (1999).
7. Bastiaens, M. T. et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am. J. Hum. Genet. 68, 884-894 (2001).
8. Box, N. F. et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J. Invest. Dermatol. 116, 224-229 (2001).
9. Gudbjartsson, D. F. et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat. Genet. 40, 886-891 (2008).
10. Stacey, S. N. et al. New common variants affecting susceptibility to basal cell carcinoma. Nat. Genet. 41, 909-914 (2009).
11. Nan, H., Kraft, P., Hunter, D. J. & Han, J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int. J. Cancer 125, 909-917 (2009).
12. Han, J. et al. A germline variant in the interferon regulatory factor 4 gene as a novel skin cancer risk locus. Cancer Res. 71, 1533-1539 (2011).
13. Praetorius, C. et al. A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 155, 1022-1033 (2013).
14. Stacey, S. N. et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat. Genet. 40, 1313-1318 (2008).
15. Stacey, S. N. et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat. Genet. 43, 1098-1103 (2011).
16. Stacey, S. N. et al. Germline sequence variants in TGM3 and RGS22 confer risk of basal cell carcinoma. Hum. Mol. Genet. 23, 3045-3053 (2014).
17. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221-227 (2009).
18. Sigurdardottir, L. G. et al. Data quality at the Icelandic Cancer Registry: comparability, validity, timeliness and completeness. Acta Oncol. 51, 880-889 (2012).
19. Kong, A. et al. Detection of sharing by descent, long-range phasing and haplotype imputation. Nat. Genet. 40, 1068-1075 (2008).
20. Kong, A. et al. Parental origin of sequence variants associated with complex diseases. Nature 462, 868-874 (2009).
21. Steinthorsdottir, V. et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat. Genet. 46, 294-298 (2014).
22. Choi, E. & Cho, C. Expression of a sperm flagellum component encoded by the Als2cr12 gene. Gene Expr. Patterns 11, 327-333 (2011).
23. Van Raam, B. J. & Salvesen, G. S. Proliferative versus apoptotic functions of caspase-8 Hetero or homo: the caspase-8 dimer controls cell fate. Biochim. Biophys. Acta 1824, 113-122 (2012).
24. Jones, E. A., Sajid, M. I., Shenton, A. & Evans, D. G. Basal cell carcinomas in gorlin syndrome: a review of 202 patients. J. Skin Cancer 2011, 217378 (2011).
25. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310-315 (2014).
26. Emilsson, V. et al. Genetics of gene expression and its effect on disease. Nature 452, 423-428 (2008).
27. Horiuchi, T. et al. Dominant expression of a novel splice variant of caspase-8 in human peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 272, 877-881 (2000).
28. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V. & Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85, 803-815 (1996).
29. Eckhart, L. et al. Alternative splicing of caspase-8 mRNA during differentiation of human leukocytes. Biochem. Biophys. Res. Commun. 289, 777-781 (2001).
30. Nagy, E. & Maquat, L. E. A rule for termination-codon position within introncontaining genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 23, 198-199 (1998).
31. Muzio, M. et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - inducing signaling complex. Cell 85, 817-827 (1996).
32. Scaffidi, C., Medema, J. P., Krammer, P. H. & Peter, M. E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 272, 26953-26958 (1997).
33. Himeji, D. et al. Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood 99, 4070-4078 (2002).
34. Mohr, A. et al. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 24, 2421-2429 (2005).
35. GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat. Genet. 45, 580-585 (2013).
36. MacPherson, G. et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J. Natl Cancer Inst. 96, 1866-1869 (2004).
37. Cox, A. et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39, 352-358 (2007).
38. Barrett, J. H. et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat. Genet. 43, 1108-1113 (2011).
39. Berndt, S. I. et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat. Genet. 45, 868-876 (2013).
40. Sun, T. et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat. Genet. 39, 605-613 (2007).
41. Haiman, C. A. et al. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat. Genet. 40, 259-260 (2008).
42. Lin, W.-Y. et al. Identification and characterisation of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum. Mol. Genet. 24, 285-298 (2014).
43. Huang, M. & Weiss, W. A. Neuroblastoma and MYCN. Cold Spring Harb. Perspect. Med. 3, a014415 (2013).
44. Roussel, M. F. & Robinson, G. W. Role of MYC in medulloblastoma. Cold Spring Harb. Perspect. Med. 3, a014308 (2013).
45. Eckhart, L., Lippens, S., Tschachler, E. & Declercq, W. Cell death by cornification. Biochim. Biophys. Acta 1833, 3471-3480 (2013).
46. Kovalenko, A. et al. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J. Exp. Med. 206, 2161-2177 (2009).
47. Lee, P. et al. Dynamic expression of epidermal caspase 8 simulates a wound healing response. Nature 458, 519-523 (2009).
48. Kaiser r, W. J. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368-372 (2011).
49. Park, W. S. et al. Inactivating mutations of the caspase-10 gene in gastric cancer. Oncogene 21, 2919-2925 (2002).
50. Shin, M. S. et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99, 4094-4099 (2002).
51. Sanna, M. G. et al. ILPIP, a novel anti-apoptotic protein that enhances XIAPmediated activation of JNK1 and protection against apoptosis. J. Biol. Chem. 277, 30454-30462 (2002).
52. Chou, J., Provot, S. & Werb, Z. GATA3 in development and cancer differentiation: cells GATA have it! J. Cell. Physiol. 222, 42-49 (2010).
53. Kurek, D., Garinis, G. A., van Doorninck, J. H., van der Wees, J. & Grosveld, F. G. Transcriptome and phenotypic analysis reveals Gata3-dependent signalling pathways in murine hair follicles. Development 134, 261-272 (2007).
54. Kaufman, C. K. et al. GATA-3: an unexpected regulator of cell lineage determination in skin. Genes Dev. 17, 2108-2122 (2003).
55. Rácz, E. et al. GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4. PLoS ONE 6, e19806 (2011).
56. De Guzman Strong, C. et al. Lipid defect underlies selective skin barrier impairment of an epidermal-specific deletion of Gata-3. J. Cell Biol. 175, 661-670 (2006).
57. Ouyang, W. et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 12, 27-37 (2000).
58. Tjønneland, A. et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand. J. Public Health 35, 432-441 (2007).
59. Dunham, I. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
60. ENCODE. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9, e1001046 (2011).
61. Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43-49 (2011).
62. Chadwick, L. H. The NIH Roadmap Epigenomics Program data resource. Epigenomics 4, 317-324 (2012).
63. Sheffield, N. C. et al. Patterns of regulatory activity across diverse human cell types predict tissue identity, transcription factor binding, and long-range interactions. Genome Res. 23, 777-788 (2013).
64. Davydov, E. V. et al. Identifying a high fraction of the human genome to be under selective constraint using GERP ++. PLoS Comput. Biol. 6, e1001025 (2010).
65. Garber, M. et al. Identifying novel constrained elements by exploiting biased substitution patterns. Bioinformatics 25, i54-i62 (2009).
66. Wang, J. et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res. 22, 1798-1812 (2012).
67. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2011).
68. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).